Bristol-Myers Squibb Company
Organization details
- Legal name
- Bristol-Myers Squibb Company
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Princeton
- Headquarters state / province
- New Jersey
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BMY
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0000014272
- EIN
- 22-0790350
- Wikidata ID
- Q266423
Board of directors
-
Christopher S. Boerner · Director · Chief Executive OfficerSince 2024
-
Deepak Bhatt · DirectorSince 2023
-
Derica W. Rice · DirectorSince 2023
-
Gerald L. Storch · DirectorSince 2023
-
Giovanni Caforio · Director · Executive Chair of the BoardSince 2023
-
Julia A. Haller · DirectorSince 2023
-
Karen H. Vousden · DirectorSince 2023
-
Medina Manuel Hidalgo · DirectorSince 2023
-
Michael R. McMullen · DirectorSince 2024
-
Paula A. Price · DirectorSince 2023
-
Peter J. Arduini · DirectorSince 2023
-
Phyllis R. Yale · DirectorSince 2023
-
Theodore R. Samuels II · DirectorSince 2023
Chief executives
Strong · grade B
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 50% of the scoring weight is on file.
- Dividends 15%
- 68
- Revenue growth 20%
- 81
- Earnings growth 15%
- 80
dividend grew 5% a year
10.6% a year in revenue
10.1% a year in earnings per share
50% of the scoring weight is on file. Figures cover December 2014 – December 2025.
Director election results
Annual meeting of May 5, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.2%
-
96.9%
-
96.9%
-
97.2%
-
98.1%
-
98.5%
-
98.9%
-
99.0%
-
99.5%
Board connections
11 of this board's directors also sit on 17 other boards. 6 are in the same sector.
- via Paula A. Price
- via Michael R. McMullen
- via Theodore R. Samuels II
- via Christopher S. Boerner
-
DaVita Inc. Same sectorvia Phyllis R. Yale
-
Faeth Therapeutics Inc. Same sectorvia Karen H. Vousden
-
GE HealthCare Technologies Inc. Same sectorvia Peter J. Arduini
-
Guardant Health Inc. Same sectorvia Medina Manuel Hidalgo
- via Theodore R. Samuels II
- via Michael R. McMullen
- via Paula A. Price
-
Outlook Therapeutics Inc. Same sectorvia Julia A. Haller
-
Stryker Corporation Same sectorvia Giovanni Caforio
- via Derica W. Rice
- via Derica W. Rice
- via Derica W. Rice
- via Paula A. Price
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $2,527,842
- 5 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5, 2026 | Julia A. Haller Director | Open-market sale | −3,800 | $63.31 | $240,578 |
| Nov 3, 2026 | Lenkowsky Adam Officer (EVP, Chief Commercial Officer) | Option exercise | +7,522 | — | — |
| Nov 3, 2026 | Lenkowsky Adam Officer (EVP, Chief Commercial Officer) | Shares withheld for tax | −3,848 | $61.71 | $237,460 |
| Nov 1, 2026 | Christopher S. Boerner Director, Officer (Chief Executive Officer) | Option exercise | +2,964 | — | — |
| Nov 1, 2026 | Meyers Gregory Scott Officer (EVP, Chief Digital & Tech Off.) | Option exercise | +6,281 | — | — |
| Nov 1, 2026 | Shanahan Karin Officer (EVP, Chief Supply Chain & Ops) | Option exercise | +6,281 | — | — |
| Nov 1, 2026 | Christopher S. Boerner Director, Officer (Chief Executive Officer) | Other | +406 | — | — |
| Nov 1, 2026 | Meyers Gregory Scott Officer (EVP, Chief Digital & Tech Off.) | Shares withheld for tax | −2,665 | $62.48 | $166,509 |
| Nov 1, 2026 | Shanahan Karin Officer (EVP, Chief Supply Chain & Ops) | Shares withheld for tax | −3,213 | $62.48 | $200,748 |
| Nov 1, 2026 | Christopher S. Boerner Director, Officer (Chief Executive Officer) | Shares withheld for tax | −1,724 | $62.48 | $107,716 |
| Oct 2, 2026 | Gallman Cari Officer (EVP, General Counsel) | Option exercise | +4,559 | — | — |
| Oct 2, 2026 | Gallman Cari Officer (EVP, General Counsel) | Shares withheld for tax | −2,332 | $61.15 | $142,602 |
| Sep 9, 2026 | Massacesi Cristian Officer (EVP,Chief Med Offr,Head of Dev) | Open-market sale | −6,249 | $64.57 | $403,498 |
| Sep 1, 2026 | Short Bartie Wendy Officer (EVP, Corporate Affairs) | Option exercise | +1,236 | $66.92 | $82,713 |
| Sep 1, 2026 | Short Bartie Wendy Officer (EVP, Corporate Affairs) | Shares withheld for tax | −633 | $66.92 | $42,360 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Bristol-Myers Squibb Company
Who is the CEO of Bristol-Myers Squibb Company?
Giovanni Caforio has been Bristol-Myers Squibb Company's Board Chair and CEO since May 2015.
How many directors are on Bristol-Myers Squibb Company's board?
Bristol-Myers Squibb Company's board has 13 directors: Christopher S. Boerner, Deepak Bhatt, Derica W. Rice, Gerald L. Storch, Giovanni Caforio, Julia A. Haller, Karen H. Vousden, Medina Manuel Hidalgo, Michael R. McMullen, Paula A. Price and 3 others.
Are Bristol-Myers Squibb Company insiders buying or selling shares?
Over the last 12 months, Bristol-Myers Squibb Company insiders made no open-market purchases and sold $2.5 million of shares in 5 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="bristol-myers-squibb-company"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.